サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1776819

神経障害性疼痛市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)

Neuropathic Pain Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 191 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
神経障害性疼痛市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)
出版日: 2025年07月22日
発行: Persistence Market Research
ページ情報: 英文 191 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の神経障害性疼痛市場に関する包括的な分析を発表しました。当レポートでは、市場促進要因・動向・機会・課題などの重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。当レポートは、世界の神経障害性疼痛市場の予測成長軌道 (2025～2032年) を概説する独占的データと統計を掲載しています。

主要な洞察

  • 神経障害性疼痛の市場規模 (2025年)：91億米ドル
  • 市場規模の予測 (金額ベース、2032年)：132億米ドル
  • 世界市場の成長率 (CAGR、2025～2032年)：5.5%

神経障害性疼痛市場 - 分析範囲

神経障害性疼痛治療の対象は、糖尿病性神経障害、帯状疱疹後神経痛、脊髄損傷、多発性硬化症、化学療法誘発性神経障害など、神経の損傷や機能障害によって引き起こされる慢性疼痛状態です。この市場には、抗うつ薬、抗けいれん薬、外用薬、オピオイドなどの医薬品による介入のほか、神経調節や理学療法などの非薬理学的アプローチも含まれます。慢性疼痛や神経障害の負担が世界的に増加していることから、病院、ペインクリニック、在宅医療の現場において、的を絞った効果的な神経障害性疼痛治療に対する需要が高まっています。

市場成長の促進要因：

世界の神経障害性疼痛市場は、糖尿病、がん、その他神経障害と強く関連する慢性疾患の有病率の上昇に後押しされています。人口の高齢化と座りがちなライフスタイルは、神経障害性疾患の発生率上昇にさらに寄与しています。神経障害性疼痛の衰弱効果に関するヘルスケア専門家や患者の意識の高まりと、専門的な治療法の利用可能性が、市場の成長を促進しています。さらに、薬理学的研究の進歩により、有効性と忍容性に優れた新規治療薬が開発され、患者のアドヒアランスと治療成績が向上しています。併用療法や標的ドラッグデリバリーシステムの採用も勢いを増しており、複雑な疼痛症候群の管理が向上しています。

市場の抑制要因：

需要の高まりにもかかわらず、神経障害性疼痛市場は、既存薬の有効性の限界、副作用のリスクの高さ、オピオイドの長期使用に伴う依存性など、いくつかの課題に直面しています。特に開発途上地域では保険償還に制限があるため、神経調節装置やブランド医薬品といった高コストの治療へのアクセスがさらに制限されています。さらに、神経障害性疼痛の臨床試験は、しばしば患者の募集や結果のばらつきといった問題に直面し、医薬品の承認や技術革新のスケジュールを遅らせています。規制の複雑さや、長期的な安全性と有効性を裏付ける確かなエビデンスの必要性は、市場参入企業にとって引き続き大きなハードルとなっています。

市場機会：

神経障害性疼痛市場は、個別化医療、生物製剤、神経刺激技術の進歩によって大きな成長機会がもたらされます。遺伝子治療、RNAベースの治療、再生医療などの調査により、より効果的で長期にわたる疼痛緩和が期待されます。デジタル治療薬やAI主導の疼痛管理プラットフォームへの投資の増加は、リアルタイムのモニタリング、早期介入、患者エンゲージメントの強化を可能にします。さらに、製薬会社、研究機関、バイオテクノロジー企業間の戦略的提携により、次世代神経障害性疼痛ソリューションのパイプラインが加速しています。ヘルスケアのインフラが改善し、疾患に対する認識が高まっている新興市場への進出は、市場プレーヤーに新たな収益源を提供します。

当レポートで回答する主な質問

  • 神経障害性疼痛市場の世界の成長を促進する主な要因は何か？
  • 神経障害性疼痛治療の採用を牽引している治療方法と薬剤クラスは何か？
  • 技術の進歩は神経障害性疼痛市場の競合情勢をどのように変えているのか？
  • 神経障害性疼痛市場に貢献している主要企業はどれか、また市場の関連性を維持するためにどのような戦略を採用しているか？
  • 世界の神経障害性疼痛治療の新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • COVID-19の影響分析
  • 予測要因：関連性と影響

第3章 付加価値分析

  • 疾病疫学
  • バリューチェーン分析
  • 技術評価
  • 製品の採用/使用状況分析
  • 最近の製品承認と発売
  • 主要な市場プレーヤー
  • 規制状況
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の神経障害性疼痛市場の展望

  • 主なハイライト
    • 市場規模と前年比成長率 (金額ベース)
    • 絶対的収益機会
  • 市場規模の分析と予測 (金額ベース)
    • 過去の市場規模の分析 (金額ベース、2019～2024年)
    • 現在の市場規模の分析と予測 (金額ベース、2025～2032年)
  • 世界の神経障害性疼痛市場の展望：薬剤クラス別
    • 過去の市場規模の分析：薬剤クラス別 (金額ベース、2019～2024年)
    • 現在の市場規模の予測：薬剤クラス別 (金額ベース、2025～2032年)
      • 三環系抗うつ薬
      • 抗けいれん薬
      • SNRI
      • 局所麻酔薬
      • オピオイド
      • その他
    • 市場魅力分析：薬剤クラス別
  • 世界の神経障害性疼痛市場の展望：適応症別
    • 過去の市場規模の分析：適応症別 (金額ベース、2019～2024年)
    • 現在の市場規模の予測：適応症別 (金額ベース、2025～2032年)
      • 糖尿病性神経障害
      • 化学療法誘発性末梢神経障害（CIPN）
      • 帯状疱疹後神経痛（PHN）
      • 三叉神経痛
      • 脊髄損傷関連神経障害
      • 幻肢痛
      • 多発性硬化症関連神経障害
      • その他
    • 市場魅力分析：適応症別
  • 世界の神経障害性疼痛市場の展望：投与経路別
    • 過去の市場規模の分析：投与経路別 (金額ベース、2019～2024年)
    • 現在の市場規模の予測：投与経路別 (金額ベース、2025～2032年)
      • 経口
      • 局所
      • 非経口
    • 市場魅力分析：投与経路別
  • 世界の神経障害性疼痛市場の展望：流通チャネル別
    • 過去の市場規模の分析：流通チャネル別 (金額ベース、2019～2024年)
    • 現在の市場規模の予測：流通チャネル別 (金額ベース、2025～2032年)
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 市場魅力分析：流通チャネル別

第5章 世界の神経障害性疼痛市場の展望：地域別

  • 過去の市場規模の分析：地域別 (金額ベース、2019～2024年)
  • 現在の市場規模の予測：地域別 (金額ベース、2025～2032年)
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • 中東・アフリカ
  • 市場魅力分析：地域別

第6章 北米の神経障害性疼痛市場の展望

第7章 欧州の神経障害性疼痛市場の展望

第8章 東アジアの神経障害性疼痛市場の展望

第9章 南アジア・オセアニアの神経障害性疼痛市場の展望

第10章 ラテンアメリカの神経障害性疼痛市場の展望

第11章 中東・アフリカの神経障害性疼痛市場の展望

第12章 競合情勢

  • 市場シェア分析、2024年
  • 市場構造
    • 市場別競合強度マップ
    • 競合ダッシュボード
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Almatica
    • Vertex Pharmaceuticals Incorporated
    • Azurity Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Viatris Inc.
    • Supernus Pharmaceuticals, Inc.
    • Novartis AG
    • Accord Healthcare
    • Focus Health Group
    • ABneal Pharmaceuticals LLC.
    • Abbott
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章 付録

  • 調査手法
  • 調査の前提
  • 頭字語と略語
目次
Product Code: PMRREP4149

Persistence Market Research has recently released a comprehensive report on the worldwide market for neuropathic pain treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neuropathic pain market from 2025 to 2032.

Key Insights:

  • Neuropathic Pain Market Size (2025E): USD 9.1 Billion
  • Projected Market Value (2032F): USD 13.2 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Neuropathic Pain Market - Report Scope:

Neuropathic pain treatment targets chronic pain conditions caused by nerve damage or dysfunction, including diabetic neuropathy, post-herpetic neuralgia, spinal cord injury, multiple sclerosis, and chemotherapy-induced neuropathy. The market encompasses pharmaceutical interventions such as antidepressants, anticonvulsants, topical agents, and opioids, as well as non-pharmacological approaches including neuromodulation and physical therapy. The increasing burden of chronic pain and neurological disorders globally has led to a growing demand for targeted and effective neuropathic pain treatments across hospitals, pain clinics, and homecare settings.

Market Growth Drivers:

The global neuropathic pain market is propelled by the rising prevalence of diabetes, cancer, and other chronic conditions that are strongly associated with nerve damage. Aging populations and sedentary lifestyles further contribute to the increased incidence of neuropathic conditions. Growing awareness among healthcare professionals and patients regarding the debilitating effects of neuropathic pain and the availability of specialized treatments is fostering market growth. Moreover, advancements in pharmacological research have led to the development of novel therapeutics with better efficacy and tolerability, enhancing patient adherence and outcomes. The adoption of combination therapy and targeted drug delivery systems is also gaining momentum, offering improved management of complex pain syndromes.

Market Restraints:

Despite the growing demand, the neuropathic pain market faces several challenges, including limited effectiveness of existing medications, high risk of side effects, and dependence associated with long-term use of opioids. Reimbursement limitations, especially in developing regions, further restrict access to high-cost treatments such as neuromodulation devices or branded pharmaceuticals. Additionally, clinical trials for neuropathic pain often face difficulties in patient recruitment and outcome variability, delaying drug approvals and innovation timelines. Regulatory complexities and the need for robust evidence supporting long-term safety and efficacy continue to pose significant hurdles for market participants.

Market Opportunities:

The neuropathic pain market presents substantial growth opportunities driven by advancements in personalized medicine, biologics, and neurostimulation technologies. Research into gene therapy, RNA-based treatments, and regenerative medicine holds promise for more effective and long-lasting pain relief. Increasing investment in digital therapeutics and AI-driven pain management platforms enables real-time monitoring, early intervention, and enhanced patient engagement. Moreover, strategic collaborations among pharmaceutical companies, research institutions, and biotech firms are accelerating the pipeline of next-generation neuropathic pain solutions. Expansion into emerging markets with improving healthcare infrastructure and rising disease awareness offers new revenue streams for market players.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the neuropathic pain market globally?
  • Which treatment modalities and drug classes are leading the adoption of neuropathic pain therapies?
  • How are technological advancements reshaping the competitive landscape of the neuropathic pain market?
  • Who are the key players contributing to the neuropathic pain market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global neuropathic pain treatment landscape?

Competitive Intelligence and Business Strategy:

These companies invest in next-generation analgesics, including sodium channel blockers, TRPV1 antagonists, and monoclonal antibodies to overcome limitations of existing therapies. Collaborative research initiatives and acquisitions aimed at enhancing R&D capabilities and expanding therapeutic portfolios are key strategies. Additionally, companies are emphasizing patient-centric approaches, digital engagement tools, and education campaigns to support diagnosis, treatment adherence, and quality of life improvements.

Key Companies Profiled:

  • Almatica
  • Vertex Pharmaceuticals Incorporated
  • Azurity Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Viatris Inc.
  • Supernus Pharmaceuticals, Inc.
  • Novartis AG
  • Accord Healthcare
  • Focus Health Group
  • Amneal Pharmaceuticals LLC
  • Abbott
  • Teva Pharmaceutical Industries Ltd.
  • Others

Neuropathic Pain Market Research Segmentation:

The neuropathic pain market encompasses a diverse range of drug classes, indications, treatment approaches, and end-user segments.

By Drug Class

  • Tricyclic Anti-Depressants
  • Anticonvulsants
  • SNRI's
  • Topical Anesthetics
  • Opioids
  • Others

By Indication

  • Diabetic Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  • Post-Herpetic Neuralgia (PHN)
  • Trigeminal Neuralgia
  • Spinal Cord Injury-Associated Neuropathy
  • Phantom Limb Pain
  • Multiple Sclerosis-Associated Neuropathy
  • Others

By Route of Administration

  • Oral
  • Topical
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Neuropathic Pain Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Disease Epidemiology
  • 3.2. Value Chain Analysis
  • 3.3. Technology Assessment
  • 3.4. Product Adoption / Usage Analysis
  • 3.5. Recent Product Approvals & Launches
  • 3.6. Key Market Players
  • 3.7. Regulatory Landscape
  • 3.8. PESTLE Analysis
  • 3.9. Porter's Five Force Analysis

4. Global Neuropathic Pain Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Neuropathic Pain Market Outlook: Drug Class
    • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
    • 4.3.2. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
      • 4.3.2.1. Tricyclic Anti-Depressants
      • 4.3.2.2. Anticonvulsants
      • 4.3.2.3. SNRI's
      • 4.3.2.4. Topical Anesthetics
      • 4.3.2.5. Opioids
      • 4.3.2.6. Others
    • 4.3.3. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Neuropathic Pain Market Outlook: Indication
    • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
    • 4.4.2. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
      • 4.4.2.1. Diabetic Neuropathy
      • 4.4.2.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
      • 4.4.2.3. Post-Herpetic Neuralgia (PHN)
      • 4.4.2.4. Trigeminal Neuralgia
      • 4.4.2.5. Spinal Cord Injury-Associated Neuropathy
      • 4.4.2.6. Phantom Limb Pain
      • 4.4.2.7. Multiple Sclerosis-Associated Neuropathy
      • 4.4.2.8. Others
    • 4.4.3. Market Attractiveness Analysis: Indication
  • 4.5. Global Neuropathic Pain Market Outlook: Route of Administration
    • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
    • 4.5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
      • 4.5.2.1. Oral
      • 4.5.2.2. Topical
      • 4.5.2.3. Parenteral
    • 4.5.3. Market Attractiveness Analysis: Route of Administration
  • 4.6. Global Neuropathic Pain Market Outlook: Distribution Channel
    • 4.6.1. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
    • 4.6.2. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
      • 4.6.2.1. Hospital Pharmacies
      • 4.6.2.2. Retail Pharmacies
      • 4.6.2.3. Online Pharmacies
    • 4.6.3. Market Attractiveness Analysis: Distribution Channel

5. Global Neuropathic Pain Market Outlook: Region

  • 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Region, 2025-2032
    • 5.2.1. North America
    • 5.2.2. Latin America
    • 5.2.3. Europe
    • 5.2.4. East Asia
    • 5.2.5. South Asia and Oceania
    • 5.2.6. Middle East & Africa
  • 5.3. Market Attractiveness Analysis: Region

6. North America Neuropathic Pain Market Outlook

  • 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.1.1. By Country
    • 6.1.2. By Drug Class
    • 6.1.3. By Indication
    • 6.1.4. By Route of Administration
    • 6.1.5. By Distribution Channel
  • 6.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
    • 6.3.1. Tricyclic Anti-Depressants
    • 6.3.2. Anticonvulsants
    • 6.3.3. SNRI's
    • 6.3.4. Topical Anesthetics
    • 6.3.5. Opioids
    • 6.3.6. Others
  • 6.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
    • 6.4.1. Diabetic Neuropathy
    • 6.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
    • 6.4.3. Post-Herpetic Neuralgia (PHN)
    • 6.4.4. Trigeminal Neuralgia
    • 6.4.5. Spinal Cord Injury-Associated Neuropathy
    • 6.4.6. Phantom Limb Pain
    • 6.4.7. Multiple Sclerosis-Associated Neuropathy
    • 6.4.8. Others
  • 6.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
    • 6.5.1. Oral
    • 6.5.2. Topical
    • 6.5.3. Parenteral
  • 6.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies
    • 6.6.3. Online Pharmacies
  • 6.7. Market Attractiveness Analysis

7. Europe Neuropathic Pain Market Outlook

  • 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Drug Class
    • 7.1.3. By Indication
    • 7.1.4. By Route of Administration
    • 7.1.5. By Distribution Channel
  • 7.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Russia
    • 7.2.7. Rest of Europe
  • 7.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
    • 7.3.1. Tricyclic Anti-Depressants
    • 7.3.2. Anticonvulsants
    • 7.3.3. SNRI's
    • 7.3.4. Topical Anesthetics
    • 7.3.5. Opioids
    • 7.3.6. Others
  • 7.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
    • 7.4.1. Diabetic Neuropathy
    • 7.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
    • 7.4.3. Post-Herpetic Neuralgia (PHN)
    • 7.4.4. Trigeminal Neuralgia
    • 7.4.5. Spinal Cord Injury-Associated Neuropathy
    • 7.4.6. Phantom Limb Pain
    • 7.4.7. Multiple Sclerosis-Associated Neuropathy
    • 7.4.8. Others
  • 7.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
    • 7.5.1. Oral
    • 7.5.2. Topical
    • 7.5.3. Parenteral
  • 7.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies
    • 7.6.3. Online Pharmacies
  • 7.7. Market Attractiveness Analysis

8. East Asia Neuropathic Pain Market Outlook

  • 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Drug Class
    • 8.1.3. By Indication
    • 8.1.4. By Route of Administration
    • 8.1.5. By Distribution Channel
  • 8.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
    • 8.2.1. China
    • 8.2.2. Japan
    • 8.2.3. South Korea
  • 8.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
    • 8.3.1. Tricyclic Anti-Depressants
    • 8.3.2. Anticonvulsants
    • 8.3.3. SNRI's
    • 8.3.4. Topical Anesthetics
    • 8.3.5. Opioids
    • 8.3.6. Others
  • 8.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
    • 8.4.1. Diabetic Neuropathy
    • 8.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
    • 8.4.3. Post-Herpetic Neuralgia (PHN)
    • 8.4.4. Trigeminal Neuralgia
    • 8.4.5. Spinal Cord Injury-Associated Neuropathy
    • 8.4.6. Phantom Limb Pain
    • 8.4.7. Multiple Sclerosis-Associated Neuropathy
    • 8.4.8. Others
  • 8.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
    • 8.5.1. Oral
    • 8.5.2. Topical
    • 8.5.3. Parenteral
  • 8.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies
    • 8.6.3. Online Pharmacies
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Neuropathic Pain Market Outlook

  • 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Drug Class
    • 9.1.3. By Indication
    • 9.1.4. By Route of Administration
    • 9.1.5. By Distribution Channel
  • 9.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
    • 9.2.1. India
    • 9.2.2. Indonesia
    • 9.2.3. Thailand
    • 9.2.4. Singapore
    • 9.2.5. ANZ
    • 9.2.6. Rest of South Asia & Oceania
  • 9.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
    • 9.3.1. Tricyclic Anti-Depressants
    • 9.3.2. Anticonvulsants
    • 9.3.3. SNRI's
    • 9.3.4. Topical Anesthetics
    • 9.3.5. Opioids
    • 9.3.6. Others
  • 9.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
    • 9.4.1. Diabetic Neuropathy
    • 9.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
    • 9.4.3. Post-Herpetic Neuralgia (PHN)
    • 9.4.4. Trigeminal Neuralgia
    • 9.4.5. Spinal Cord Injury-Associated Neuropathy
    • 9.4.6. Phantom Limb Pain
    • 9.4.7. Multiple Sclerosis-Associated Neuropathy
    • 9.4.8. Others
  • 9.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
    • 9.5.1. Oral
    • 9.5.2. Topical
    • 9.5.3. Parenteral
  • 9.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies
    • 9.6.3. Online Pharmacies
  • 9.7. Market Attractiveness Analysis

10. Latin America Neuropathic Pain Market Outlook

  • 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Drug Class
    • 10.1.3. By Indication
    • 10.1.4. By Route of Administration
    • 10.1.5. By Distribution Channel
  • 10.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of Latin America
  • 10.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
    • 10.3.1. Tricyclic Anti-Depressants
    • 10.3.2. Anticonvulsants
    • 10.3.3. SNRI's
    • 10.3.4. Topical Anesthetics
    • 10.3.5. Opioids
    • 10.3.6. Others
  • 10.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
    • 10.4.1. Diabetic Neuropathy
    • 10.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
    • 10.4.3. Post-Herpetic Neuralgia (PHN)
    • 10.4.4. Trigeminal Neuralgia
    • 10.4.5. Spinal Cord Injury-Associated Neuropathy
    • 10.4.6. Phantom Limb Pain
    • 10.4.7. Multiple Sclerosis-Associated Neuropathy
    • 10.4.8. Others
  • 10.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
    • 10.5.1. Oral
    • 10.5.2. Topical
    • 10.5.3. Parenteral
  • 10.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies
    • 10.6.3. Online Pharmacies
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Neuropathic Pain Market Outlook

  • 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Drug Class
    • 11.1.3. By Indication
    • 11.1.4. By Route of Administration
    • 11.1.5. By Distribution Channel
  • 11.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
    • 11.2.1. GCC Countries
    • 11.2.2. Egypt
    • 11.2.3. South Africa
    • 11.2.4. Northern Africa
    • 11.2.5. Rest of Middle East & Africa
  • 11.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
    • 11.3.1. Tricyclic Anti-Depressants
    • 11.3.2. Anticonvulsants
    • 11.3.3. SNRI's
    • 11.3.4. Topical Anesthetics
    • 11.3.5. Opioids
    • 11.3.6. Others
  • 11.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
    • 11.4.1. Diabetic Neuropathy
    • 11.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
    • 11.4.3. Post-Herpetic Neuralgia (PHN)
    • 11.4.4. Trigeminal Neuralgia
    • 11.4.5. Spinal Cord Injury-Associated Neuropathy
    • 11.4.6. Phantom Limb Pain
    • 11.4.7. Multiple Sclerosis-Associated Neuropathy
    • 11.4.8. Others
  • 11.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
    • 11.5.1. Oral
    • 11.5.2. Topical
    • 11.5.3. Parenteral
  • 11.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Retail Pharmacies
    • 11.6.3. Online Pharmacies
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Almatica
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Sources
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Vertex Pharmaceuticals Incorporated
    • 12.3.3. Azurity Pharmaceuticals, Inc.
    • 12.3.4. Pfizer Inc.
    • 12.3.5. Viatris Inc.
    • 12.3.6. Supernus Pharmaceuticals, Inc.
    • 12.3.7. Novartis AG
    • 12.3.8. Accord Healthcare
    • 12.3.9. Focus Health Group
    • 12.3.10. ABneal Pharmaceuticals LLC.
    • 12.3.11. Abbott
    • 12.3.12. Teva Pharmaceutical Industries Ltd.
    • 12.3.13. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations